Hypothalamic and Pituitary Hormones DSA Flashcards Preview

Endo II > Hypothalamic and Pituitary Hormones DSA > Flashcards

Flashcards in Hypothalamic and Pituitary Hormones DSA Deck (72):
1

somatotropin

GH

2

octreotride

somatostatin analog

3

pegvisomant

GH antagonist

4

bromocriptin

dopamine agonist

5

cabergoline

dopamine agonist

6

vasopressin

ADH

7

desmopressin

vasopressin receptor agonist

8

neurons of posterior pituitary

supraoptic nuclei
paraventricular nuclei

synthesize arginine vasopressin or oxytocin

9

GH signaling

JAK/STAT

single chain proteins

10

PRL signaling

JAK/STAT

single chain proteins

11

thyrotropin

TSH

12

TSH signaling

GPCRs

dimeric proteins

13

FSH signaling

GPCRs

dimeric proteins

14

LH signaling

GPCRs

dimeric proteins

15

ACTH signaling

GPCRs

cleaved from precursor beta endorphin

single peptide

16

TSH release

regulated by TRH

17

LH and FSH release

regulated by GnRH

18

ACTH release

regulated by CRH

19

TSH and TRH release

negative feedback from T4 and T3

20

FSH, LH, and GnRH release

negative feedback from estrogen/progesterone (F) and androgens (M)

21

ACTH and CRH release

negative feedback from cortisol

22

GH release

stimulated by GHRH

inhibited by somatostatin

23

somatostatin

negative feedback on GH release

24

GH release

inhibited by GH and IGF-1

25

PRL release

negative feedback from dopamine via D2 receptors

26

disruption of hypothalamohypophysial portal vessels

increase PRL

decrease ACTH, GH, LH, FSH, TSH

27

target organ of GH

liver, muscle, bone, kidney

IFG-1 mediator

28

somatotropin

aka GH

29

ACTH target organ

adrenal cortex

glucocorticoid, mineralocorticoid, androgen release

30

GnRH release

endogenous - pulsatile - stimulates LH and FSH

continuously as drug - inhibit LH and FSH

31

somatropin

recombinant human form of rhGH

32

GH function

stimulates long bone growth

anabolic effects in muscle

catabolic effects in lipid cells

33

GH and IGF-1 on insulin

GH reduces insulin sensitivity

IGF-1 losers serum glucose and reduces insulin

34

GH deficiency in children

rhGH
-permits children with short stature to achieve normal height

35

GH deficiency in adults

generalized obesity, reduced muscle mass, asthenia, reduced cardiac output

tx with rhGH reverses many of these symptoms

36

GH treatment of kids with short stature

prader-willi
turner
noonan
idiopathic short stature

37

wasting in AIDS patients

GH tx

38

adverse effects of GH in kids

rare - intracranial HTN - vision changes, HA, N/V

scoliosis
otitis media
turner syndrome
hypothyroidism
pancreatitis
gynecomastia

39

adverse effects of GH in adults

peripheral edema
myalgias
arthralgias
carpal tunnel syndrome

40

known active malignancy

contraindication for GH

41

mecasermin

recombinant IGF-1

in children with rare IGF-1 deficiency not responsive to GH - due to mutation in GH receptor

subQ admin**

42

adverse of mecasermin

hypoglycemia

so just eat before

43

anterior pituitary adenoma secreting GH

tx - GH antagonist

can cause acromegaly in adults and gigantism in children

44

MOA of pegvisoman

GH receptor antagonist

45

somatostatin analog MOA

suppression of GH secretion

46

dopamine receptor agonist

can be used to suppress GH secretion

47

somatostatin function

inhibit release of GH, TSH, glucagon, insulin, gastrin

48

octreotide

somatostatin analog

45x more potent than SST in inhibiting GH release and 2x as potent in reducing insulin secretion

49

octreotide admin

subQ

50

adverse effects of octreotide

N/V, abdominal cramping, flatulence
steatorrhea
bulky bowel movements
gallstones
cardiac effects
vit B12 deficiency

51

lanreotide

SST analog
-approved for tx of acromegaly

52

pegvisomant MOA

GH receptor antagonist

53

tx of acromegaly

pegvisomant more effective than SST analogs

54

male hyperPRL

loss of libido and infertility

55

female hyperPRL

galactorrhea and amenorrhea

56

inhibition of PRL

dopamine agonists

57

hypogonadims and infertility with hyper PRL

result from inhibition of GnRH release

58

bromocriptin MOA

dopamine D2 receptor agonist

ergot derivative

59

cabergoline MOA

dopamine D2 receptor agonist

ergot derivative

60

cabergoline

dopamine agonist

longer half life, higher affinity, and greater selectivity for D2 receptors

lower incidence of side effects

61

pregnancy desired

bromocriptine preferred

as dopamine agonist

62

adverse of dopamine agonists

bromocriptine and cabergoline

nausea, HA, light headed, orthostatic HTN, fatigue

psych sx occasionally

macroadenoma during pregnancy continue

microadenoma during pregnancy stop therapy

63

postpartum lactation

do not recommend dopamine agonists

increased incidence of stroke and coronary thrombosis

64

oxytocin

stimulate uterine contraction

elicits milk ejection

differs from vasopressin at positions 3 and 8 out of 9 AA peptide

65

desmopressin

long acting synthetic analog of vasopressin

with minimal V1 receptor activity and an antidiuretic to pressor ratio 4000x that of vasopressin

66

vasopressin MOA

activate V1 and V2 receptors
-GPCRs

V1 - smooth muscle cells of vascular - vasoconstriction

V2 - renal tubules - increased water permeability in collecting tubule

extrarenal V2 - regulate release of coag factor VIII and vWF

67

pituitary diabetes insipidus tx

vasopressin and desmopressin

68

coagulopathy in hem A and vWF disease tx

desmopressin

69

vasopressin CIs

CAD - vasoconstriction

70

overdose of vasopressin

hyponatremia
-seizures

71

conivaptan

vasopressin antagoninst

72

tolvaptan

vasopressin antagonist

more selective for V2